MedTrace Logo

Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)

NCT01875952 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-06-12

No results posted yet for this study

Summary

The purpose of this study is to determine of once identified to the subjects infected with human immunodeficiency virus (positive VIH), to diagnose latent Tuberculosis, and to treat her with isoniazid for six months, measuring the production of Interferon range pre and posttreatment, to evaluate this way the result of the treatment on the immune response

Conditions

  • Human Immunodeficiency Virus (HIV)
  • Tuberculosis (TB)
  • Latent Tuberculosis Infection (LTI)

Interventions

DRUG

Isoniazid

Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months

Sponsors & Collaborators

  • Instituto Nacional de Enfermedades Respiratorias

    collaborator OTHER_GOV

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    collaborator OTHER

  • Instituto Nacional de Salud Publica, Mexico

    lead OTHER

Principal Investigators

  • José Sifuentes, Doctor · Instituto Nacional de Ciencias Medicas y Nitrición Salvador Zubiran (INCMNSZ)

  • Alfredo Ponce-de-León, Doctor · Instituto Nacional de Ciencias Medicas y Nutrición (INCMNSZ)

  • Maria de Lourdes García-García, Post doctor · Instituto Nacional de Salud Publica (INSP)

  • Jose Luis Valdespino-Gómez, MD · Laboratorios Nacionales de Biológicos y Reactrivos (BIRMEX)

  • Martha Torres Rojas, Post Doctor · National Institute of Respiratory Diseases (INER)

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-06-30
Completion
2013-06-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01875952 on ClinicalTrials.gov